Arjuna is a traditional Indian heart-bark remedy. The most consistent evidence points to eased chest pain from stable angina, with weaker support for heart-failure symptoms, cholesterol, and blood pressure. This rests on small, mostly older trials, with no long-term outcome data. Safety is reassuring, mainly mild stomach upset and added effects with heart medications. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Total cholesterol | ~150–200 mg/dL | Tracks arjuna's lipid effect |
| LDL cholesterol | <100 mg/dL | Primary lipid target arjuna may lower |
| HDL cholesterol | >50 (women), >40 (men) mg/dL | May rise modestly with arjuna |
| Triglycerides | <90 mg/dL (functional) | Rounds out lipid response |
| Blood pressure | ~110–120 / 70–80 mmHg | Detects additive lowering effect |
| Resting heart rate | ~55–70 bpm | Catches additive rate-slowing with beta-blockers/digoxin |
| Fasting glucose | ~75–90 mg/dL | Screens for additive glucose lowering |
| Left ventricular ejection fraction | ~55–70% | Objective heart-function measure in heart-failure use |
| TSH / free T3 | TSH ~1–2 mIU/L; free T3 mid-range | Screens for the animal-reported thyroid effect |
| ALT / AST | <25 U/L (functional) | General safety for prolonged use |
Cadence: Baseline, again at ~6–8 weeks after starting, then every 3–6 months during continued use; more frequent blood-pressure and heart-rate checks in the first weeks for anyone on cardiac medications.